IRUS Total

Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury.

File Description SizeFormat 
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.pdfPublished version200.81 kBAdobe PDFView/Open
Title: Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury.
Authors: Tabassum, N
Zhang, H
Stebbing, J
Item Type: Journal Article
Abstract: A screen by Kost-Alimova et al.1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Issue Date: 17-Nov-2020
Date of Acceptance: 1-Nov-2020
URI: http://hdl.handle.net/10044/1/88080
DOI: 10.1016/j.xcrm.2020.100145
ISSN: 2666-3791
Start Page: 1
End Page: 2
Journal / Book Title: Cell Reports Medicine
Volume: 1
Issue: 8
Copyright Statement: © 2020 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Sponsor/Funder: Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
Funder's Grant Number: RDB01 79560
Publication Status: Published
Conference Place: United States
Online Publication Date: 2020-11-17
Appears in Collections:Department of Surgery and Cancer
Imperial College London COVID-19
Faculty of Natural Sciences

This item is licensed under a Creative Commons License Creative Commons